Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - calcium citrate,chromic chloride hexahydrate,cupric sulfate,ferrous sulfate,magnesium citrate,manganese sulfate monohydrate,potassium sulfate,selenomethionine,sodium molybdate dihydrate,zinc gluconate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ivy wellness nutraceuticals pty ltd - colecalciferol,calcium carbonate,cupric sulfate pentahydrate,heavy magnesium oxide,manganese sulfate monohydrate,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

ivy wellness nutraceuticals pty ltd - calcium carbonate,colecalciferol,cupric sulfate pentahydrate,heavy magnesium oxide,manganese sulfate monohydrate,zinc oxide -

Malta - English - Medicines Authority

gambro lundia ab - calcium chloride, dihydrate, potassium chloride, glucose anhydrous, lactic acid, magnesium chloride, hexahydrate, sodium chloride, sodium hydrogen, carbonate - solution for haemofiltration - calcium chloride dihydrate 0.257 millimole(s)/litre ; potassium chloride 0.298 millimole(s)/litre ; glucose anhydrous 1.1 millimole(s)/litre ; lactic acid 0.27 millimole(s)/litre ; magnesium chloride hexahydrate 0.102 millimole(s)/litre ; sodium chloride 6.128 millimole(s)/litre ; sodium hydrogen carbonate 2.936 millimole(s)/litre - blood substitutes and perfusion solutions

Australia - English - Department of Health (Therapeutic Goods Administration)

factors group australia pty ltd - zinc oxide, quantity: 6.223 mg (equivalent: zinc, qty 5 mg); colecalciferol, quantity: 0.0099 mg; pyridoxine hydrochloride, quantity: 6.075 mg (equivalent: pyridoxine, qty 5 mg); magnesium oxide, quantity: 66.33 mg (equivalent: magnesium, qty 40 mg); copper gluconate, quantity: 3.572 mg (equivalent: copper, qty 500 microgram); manganese gluconate, quantity: 4.38 mg (equivalent: manganese, qty 500 microgram); borax, quantity: 4.337 mg (equivalent: boron, qty 500 microgram); calcium citrate tetrahydrate, quantity: 1.186 g (equivalent: calcium, qty 250 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; glycerol; starch sodium octenyl succinate; purified water; sodium ascorbate; silicon dioxide; dl-alpha-tocopherol; sucrose; medium chain triglycerides - helps enhance/promote teeth health ; maintain/support healthy teeth ; aid/assist/helps connective tissue production/formation ; helps enhance/promote bone health ; maintain/support bone health ; aids/assists healthy bone development/growth/building ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support healthy muscle contraction function

Australia - English - Department of Health (Therapeutic Goods Administration)

symbion pty ltd - calcium carbonate, quantity: 1.5 g (equivalent: calcium, qty 600 mg); heavy magnesium oxide, quantity: 82.9 mg (equivalent: magnesium, qty 50 mg); zinc oxide, quantity: 9.34 mg (equivalent: zinc, qty 7.5 mg); cupric sulfate pentahydrate, quantity: 2.03 mg (equivalent: copper, qty 516.84 microgram); colecalciferol, quantity: 10 microgram; manganese sulfate monohydrate, quantity: 5.54 mg (equivalent: manganese, qty 1.8 mg) - tablet, film coated - excipient ingredients: medium chain triglycerides; iron oxide red; macrogol 6000; sucrose; maize starch; hypromellose; colloidal anhydrous silica; carnauba wax; crospovidone; microcrystalline cellulose; titanium dioxide; acacia; magnesium stearate; dl-alpha-tocopherol; maltodextrin - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; maintain/support healthy teeth ; maintain/support bone health ; maintain/support bone mass/density/integrity ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; maintain/support muscle function ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral/nutrient) levels in the body

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 4 g in 100 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium chloride, quantity: 5.38 g/l; calcium chloride dihydrate, quantity: 0.183 g/l; magnesium chloride hexahydrate, quantity: 0.0508 g/l; sodium lactate, quantity: 4.48 g/l; glucose monohydrate, quantity: 5.5 g/l - solution, irrigation - excipient ingredients: sodium hydroxide; water for injections - use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium chloride, quantity: 5.39 g/l; calcium chloride dihydrate, quantity: 0.183 g/l; magnesium chloride hexahydrate, quantity: 0.0508 g/l; sodium lactate, quantity: 4.48 g/l; glucose monohydrate, quantity: 5.5 g/l - solution, dialysis - excipient ingredients: sodium hydroxide; water for injections - indications: use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis.